If you have ever wanted to learn more about MRD testing (for minimal or measurable residual disease) during or after treatment and its envisioned importance in some limited duration treatment protocols, this is your week! We define it, point to the breaking news of expanded FDA approval of the clonoSEQ Assay in the bone marrow and peripheral blood for CLL patients, and invite you to Dr. Anthony Mato’s not-to-be missed Friday Webinar, “MRD: What Should It Mean to Me?” (Register below.)
Breaking News on MRD Testing: The CLL Society is pleased to share that Adaptive Biotechnologies has received expanded FDA clearance for the clonoSEQ® Assay to detect and monitor minimal (or measurable) residual disease (MRD) in patients with Chronic Lymphocytic Leukemia. This can help guide therapy for some limited duration treatment protocols. Read more here.
Definition, please! In this short video, Dr. Nitin Jain defines MRD testing. MRD may soon become recognized as the best indicator of when patients have attained such a low level of disease that their treatment could be discontinued, (“limited” or “fixed” duration).
Don’t Miss This Week! CLL Society’s Webinar on Friday, August 14 at 12:30 PM ET / 9:30 AM PT.
Limiting or stopping treatment to minimize CLL patients’ exposure to drugs (and potentially developing resistance) are targets that researchers are focusing much effort on. Join the CLL Society on Friday August 14 for our webinar “MRD: What Should it Mean to Me?” as Drs. Anthony Mato & Brian Koffman discuss MRD testing and its growing role in CLL treatment management. Register NOW!
Lymphoma Australia Virtual Conference: Our own Dr. Brian Koffman joins Dr. Matthew Davids from Dana Farber, Dr. Jason Butler from Brisbane, AU, and patient Deb Sims from Melbourne to discuss CLL at 4 PM PT August 17 or 9 AM August 18 in Australia. Please see additional information on CLL Society’s Upcoming Events Page.
At ASH 2019, Dr. Brian Koffman interviewed Dr. Nitin Jain about recent results from a clinical trial testing the combination of the highly effective targeted therapies ibrutinib (a BTK inhibitor) and venetoclax (a BCL2 inhibitor) in previously untreated patients with CLL. In the latter part of the interview, Dr. Jain mentions that achieving MRD negativity may be the best predictor of long-term outcomes.
Window of Opportunity! Funds Available for Out-of-Pocket Medication Costs for CLL Patients. The PAN Foundation helps federally and commercially insured people living with life-threatening, chronic, and rare diseases with out-of-pocket costs for their prescribed medications. Funds are currently available, but when these funds are gone, they’re gone. Act now! Learn more and apply here.
Please Complete Our Test Before Treat Survey. Prognostic testing should be done before each and every treatment decision. How much do you know about the critical tests which can predict which patients will do well on or fail certain medications? Test your knowledge and share your experience. Complete our Test Before Treat Survey! At the end of the survey you can request a free Test Before Treat bracelet!
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by investing in our work.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.